| Ytd | -23.45% | |
| 1y | -62.63% |
| Open | 1.14 | Prev Close | 1.11 | Low | 1.11 | High | 1.14 | Mkt Cap | 1.99M |
| Vol | 726.00 | Avg Vol | 59.59K | EPS | -2.27 | P/E | -0.49 | Forward P/E | -0.41 |
| Beta | 0.90 | Short Ratio | 0.18 | Inst. Own | 4.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.30 | 200-d Avg | 1.54 | 1yr Est | 16.75 |
BBLG News
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's afte
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday'
iOThree Ltd (IOTR) rose in premarket trading after strong fiscal 2026 results. Gainers include EDBL,
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds up
Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market
href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in
Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened bal
Milestone advances manufacturing readiness and supports long-term commercialization strategy Milesto
Bone Biologics Corp. (NASDAQ: BBLG - Get Free Report)'s share price fell 0.5% during trading on Wedn
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (
Bone Biologics Corporation BBLG stock is trading higher on Friday, with a session volume of 17.22 mi
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (
BURLINGTON, Mass.--(BUSINESS WIRE)---- $BBLG #Bonebiologics--Bone Biologics files U.S. patent applic
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthob
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (
Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance.
On Monday, 369 companies set new 52-week lows.
On Friday, 404 stocks made new 52-week lows.
During Monday's session, 402 companies made new 52-week lows.
On Friday, 137 stocks made new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.